Researchers from the University of Tsukuba show that angioimmunoblastic T-cell lymphoma (AITL) is dependent on T-cell receptor (TCR) signaling and that dasatinib, a multi-kinase inhibitor that targets the TCR pathway, may improve treatment outcomes.
from Medindia Health News https://ift.tt/388pimK
No comments:
Post a Comment